Technology & Science
Dec. 31, 2010
Biotech Faces More Regulation in 2011
Next year, trade groups and lawyers - biotech counsel as well as plaintiffs' attorneys - seek to influence new high-stakes rules, legislative and enforcement actions to their advantage.
Daily Journal Staff Writer
The biotechnology industry claimed victory this year with $1 billion in research-and-development tax credits and better patent protection for certain drugs in the federal health care reform bill.
But it saw some low points too with industry executives facing tough questioning in Congress over drug recalls and hundreds of millions of dollars in fines under increasingly tighter regulations for the biot...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In